Compare ClearPoint Neuro Inc (CLPT) vs Quest Diagnostics Inc (DGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Quest Diagnostics Inc — how do they compare? ClearPoint Neuro Inc trades at $15.17 (market cap $454.21M), while Quest Diagnostics Inc trades at $237.3 (market cap $26.21B). The key difference: Quest Diagnostics Inc is far larger — about 57.7× ClearPoint Neuro Inc's market cap, and Quest Diagnostics Inc pays a 1.45% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | DGX | |
|---|---|---|
Market Cap | $454.21M | $26.21B |
Sector | Health | Health |
52-Week High | $29.60 | $238.50 |
52-Week Low | $8.66 | $173.49 |
Enterprise Value | $488.79M | $31.97B |
Dividend Yield | — | 1.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $15.20, up 4.32% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue growth but missed earnings estimates, with a net income margin of -81.76%. Recent news highlights regulatory progress with partners and expansion into focused ultrasound technology.
The outlook remains speculative with high growth potential in neurotherapy markets, but significant execution and profitability risks persist. Analyst consensus is unanimously bullish, though sustained losses and cash burn require careful monitoring for long-term investors.
Quest Diagnostics (DGX) trades at $237.24, down 0.16% on the day, with a bullish technical signal from moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $3.12 and raising its full-year outlook, driven by robust testing demand. Revenue grew to $11.04B in 2025, with net income of $992M, though margins face pressure from lower-margin deals and rising costs.
The outlook is positive due to raised guidance and AI integration enhancing efficiency, but risks include debt levels and margin compression. Analysts maintain a cautious buy stance with a $249.50 price target, indicating modest upside potential from current levels amid competitive and cost challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →
